Skip to content

Observatory on Cow's Milk Protein Allergy

Prospective National Observatory for Cow's Milk Protein Allergy.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06085118
Acronym
OLAF
Enrollment
3000
Registered
2023-10-16
Start date
2024-06-17
Completion date
2031-11-30
Last updated
2024-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Allergy

Brief summary

The purpose of this study is to describe the symptoms and their evolution up to the age of 5 years in a population of newly diagnosed infants with a suspected or confirmed allergy to cow proteins, for whom the doctor prescribed the Pepticate® Syneo® replacement formula as soon as they were diagnosed. The Pepticate® Syneo® product is an advanced protein hydrolyzate, food type intended for special medical purposes. This is a product already available on the market.

Detailed description

This is a prospective, observational, descriptive, longitudinal, multicentric study aimed at describing a cohort of infants with a recently suspected or confirmed allergy to cow's milk protein, who were treated in outpatient and inpatient settings. The recruitment of patients eligible for this observatory will be done via community medicine (private practices of pediatricians and general practitioners) as well as in hospitals throughout France.

Interventions

OTHERPepticate® Syneo®

Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).

Sponsors

Nutricia Nutrition Clinique
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 8 Months
Healthy volunteers
No

Inclusion criteria

* Infants up to and including 8 months (up to 8 months and 29 days). * Initial diagnosis of allergy to cow proteins, suspected (clinical presumption) or confirmed. * Prescription of the substitution formula Pepticate® Syneo, according to the doctor's judgement, whether the child is under mixed or weaned breastfeeding. * Authorisation from a legal representative for the child to take part in the observatory and to collect personal information about the child and the family. * Membership of the social security system.

Exclusion criteria

* Infants who have already received partial or total replacement infant formula (regardless of the type of infant formula). * Contraindication to the use of symbiotics (short small intestine, parenteral nutrition, post-pyloric feeding, central venous catheter) due to the use of Pepticate® Syneo®. * Diagnosis of severe cow protein allergy requiring an infant amino acid formula from the outset. * The child's legal guardian is protected (under legal protection, or deprived of liberty by judicial or administrative decision). * The legal representative is unable to understand the study protocol.

Design outcomes

Primary

MeasureTime frameDescription
Number and proportion of symptoms5 yearsNumbers and proportion of symptoms (cutaneous, gastrointestinal, respiratory...), and their evolution according to the different forms of cow protein allergy: immediate Immunoglobulin E mediated, delayed non-Immunoglobulin E mediated or mixed and acute food protein-induced enterocolitis syndrome.

Countries

France

Contacts

Primary ContactLine JOUANNIC
line.samier@danone.com603883762

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026